{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:46:21Z","timestamp":1788907581565,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81101728"],"award-info":[{"award-number":["81101728"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070660"],"award-info":[{"award-number":["82070660"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["2018SCUH0084"],"award-info":[{"award-number":["2018SCUH0084"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ymthe.2021.09.015","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T01:10:18Z","timestamp":1632100218000},"page":"644-661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["High-dose VitC plus oncolytic adenoviruses enhance immunogenic tumor cell death and reprogram tumor immune microenvironment"],"prefix":"10.1016","volume":"30","author":[{"given":"Jinhu","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongheng","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongbing","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anliang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5440-5941","authenticated-orcid":false,"given":"Ping","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2021.09.015_bib1","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3389\/fonc.2020.01786","article-title":"The Oncolytic Virus in Cancer Diagnosis and Treatment","volume":"10","author":"Cao","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2021.09.015_bib2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2021.09.015_bib3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2021.09.015_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1158\/2159-8290.CD-NB2015-158","article-title":"First Oncolytic Viral Therapy for Melanoma","volume":"6","author":"Poh","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2021.09.015_bib5","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fonc.2019.01182","article-title":"Oncolytic Adenovirus-A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC","volume":"9","author":"Abudoureyimu","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2021.09.015_bib6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12943-020-01275-6","article-title":"Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2021.09.015_bib7","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2021.09.015_bib8","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1021\/acs.nanolett.9b00145","article-title":"Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy","volume":"19","author":"Lv","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2021.09.015_bib9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.tcb.2018.04.001","article-title":"Vitamin C in Stem Cell Reprogramming and Cancer","volume":"28","author":"Cimmino","year":"2018","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ymthe.2021.09.015_bib10","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3390\/nu9111211","article-title":"Vitamin C and Immune Function","volume":"9","author":"Carr","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.ymthe.2021.09.015_bib11","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.aad8671","article-title":"CANCER. Revisiting vitamin C and cancer","volume":"350","author":"Reczek","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.09.015_bib12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41568-019-0135-7","article-title":"Targeting cancer vulnerabilities with high-dose vitamin C","volume":"19","author":"Ngo","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2021.09.015_bib13","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nature23876","article-title":"Ascorbate regulates haematopoietic stem cell function and leukaemogenesis","volume":"549","author":"Agathocleous","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.09.015_bib14","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1038\/bcj.2017.65","article-title":"Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells","volume":"7","author":"Shenoy","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2021.09.015_bib15","doi-asserted-by":"crossref","first-page":"eaay8707","DOI":"10.1126\/scitranslmed.aay8707","article-title":"High-dose vitamin C enhances cancer immunotherapy","volume":"12","author":"Magr\u00ec","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2021.09.015_bib16","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1073\/pnas.1908158117","article-title":"High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model","volume":"117","author":"Luchtel","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.09.015_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2021.09.015_bib18","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ymthe.2021.09.015_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2021.09.015_bib20","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1111\/jcmm.14356","article-title":"Immunogenic cell death in cancer therapy: Present and emerging inducers","volume":"23","author":"Zhou","year":"2019","journal-title":"J.\u00a0Cell. Mol. Med."},{"key":"10.1016\/j.ymthe.2021.09.015_bib21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2021.05.040","article-title":"Low dose shikonin and anthracyclines coloaded liposomes induce robust immunogenetic cell death for synergistic chemo-immunotherapy","volume":"335","author":"Li","year":"2021","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.ymthe.2021.09.015_bib22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2021.09.015_bib23","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1021\/acsami.9b19323","article-title":"Restoration and Enhancement of Immunogenic Cell Death of Cisplatin by Coadministration with Digoxin and Conjugation to HPMA Copolymer","volume":"12","author":"Xiang","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ymthe.2021.09.015_bib24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-020-01297-0","article-title":"Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma","volume":"20","author":"Guo","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2021.09.015_bib25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.canlet.2018.11.015","article-title":"Electrochemotherapy with cisplatin increases survival and induces immunogenic responses in murine models of lung cancer and colorectal cancer","volume":"442","author":"Tremble","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2021.09.015_bib26","doi-asserted-by":"crossref","first-page":"50734","DOI":"10.1021\/acsami.0c14909","article-title":"Multifunctional Nanoparticles Boost Cancer Immunotherapy Based on Modulating the Immunosuppressive Tumor Microenvironment","volume":"12","author":"Li","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ymthe.2021.09.015_bib27","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fonc.2019.00564","article-title":"The Oncolytic Virus dl922-947 Triggers Immunogenic Cell Death in Mesothelioma and Reduces Xenograft Growth","volume":"9","author":"Di Somma","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2021.09.015_bib28","doi-asserted-by":"crossref","first-page":"1591875","DOI":"10.1080\/2162402X.2019.1591875","article-title":"Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma","volume":"8","author":"Bommareddy","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2021.09.015_bib29","doi-asserted-by":"crossref","first-page":"1802968","DOI":"10.1080\/2162402X.2020.1802968","article-title":"Recombinant viruses delivering the necroptosis mediator MLKL induce a potent antitumor immunity in mice","volume":"9","author":"Van Hoecke","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2021.09.015_bib30","doi-asserted-by":"crossref","first-page":"e000330","DOI":"10.1136\/jitc-2019-000330","article-title":"A recombinant oncolytic Newcastle virus expressing MIP-3\u03b1 promotes systemic antitumor immunity","volume":"8","author":"Huang","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2021.09.015_bib31","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1038\/s41375-020-0828-7","article-title":"Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma","volume":"34","author":"Packiriswamy","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2021.09.015_bib32","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2021.09.015_bib33","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/sj.cdd.4402148","article-title":"Cell death modalities: classification and pathophysiological implications","volume":"14","author":"Galluzzi","year":"2007","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ymthe.2021.09.015_bib34","doi-asserted-by":"crossref","first-page":"e000337","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2021.09.015_bib35","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2021.09.015_bib36","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2021.09.015_bib37","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.cell.2018.07.035","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"174","author":"Ribas","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2021.09.015_bib38","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2021.09.015_bib39","doi-asserted-by":"crossref","first-page":"eabc6659","DOI":"10.1126\/scitranslmed.abc6659","article-title":"Systemic cancer therapy with engineered adenovirus that evades innate immunity","volume":"12","author":"Atasheva","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2021.09.015_bib40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fonc.2020.00048","article-title":"Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment","volume":"10","author":"Luo","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2021.09.015_bib41","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2021.09.015_bib42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41573-019-0046-z","article-title":"Synthetic lethality as an engine for cancer drug target discovery","volume":"19","author":"Huang","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2021.09.015_bib43","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41571-019-0281-6","article-title":"From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer","volume":"17","author":"Nevala-Plagemann","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2021.09.015_bib44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","article-title":"Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise","volume":"17","author":"Morel","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2021.09.015_bib45","doi-asserted-by":"crossref","first-page":"46112","DOI":"10.1021\/acsami.9b15848","article-title":"Cascade-Reaction-Based Nanodrug for Combined Chemo\/Starvation\/Chemodynamic Therapy against Multidrug-Resistant Tumors","volume":"11","author":"Chen","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ymthe.2021.09.015_bib46","doi-asserted-by":"crossref","first-page":"101948","DOI":"10.1016\/j.ctrv.2019.101948","article-title":"Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice","volume":"83","author":"Bregni","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ymthe.2021.09.015_bib47","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","article-title":"Inflammatory microenvironment remodelling by tumour cells after radiotherapy","volume":"20","author":"McLaughlin","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2021.09.015_bib48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41573-019-0040-5","article-title":"Targeting metabolic dysregulation for fibrosis therapy","volume":"19","author":"Zhao","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2021.09.015_bib49","doi-asserted-by":"crossref","first-page":"eaax0182","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.09.015_bib50","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood.2019000923","article-title":"Immune dysregulation in patients with RAG deficiency and other forms of combined immune deficiency","volume":"135","author":"Delmonte","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.09.015_bib51","doi-asserted-by":"crossref","first-page":"8382","DOI":"10.7150\/thno.45391","article-title":"Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ymthe.2021.09.015_bib52","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-020-15229-5","article-title":"An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T\u00a0cell responses","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.09.015_bib53","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3390\/cells9020400","article-title":"Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy","volume":"9","author":"Nguyen","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2021.09.015_bib54","doi-asserted-by":"crossref","first-page":"e000188","DOI":"10.1136\/jitc-2019-000188","article-title":"Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity","volume":"8","author":"Santos","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2021.09.015_bib55","doi-asserted-by":"crossref","first-page":"e000710","DOI":"10.1136\/jitc-2020-000710","article-title":"Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety","volume":"8","author":"Ge","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2021.09.015_bib56","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-020-2015-4","article-title":"ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity","volume":"579","author":"Moral","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.09.015_bib57","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3390\/cancers12051295","article-title":"Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination","volume":"12","author":"Sato-Dahlman","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2021.09.015_bib58","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/s41467-020-16243-3","article-title":"Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers","volume":"11","author":"Di Tano","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.09.015_bib59","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.7150\/thno.35219","article-title":"Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK\/ERK and PI3K\/AKT pathways via distinct mechanisms","volume":"9","author":"Su","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.ymthe.2021.09.015_bib60","doi-asserted-by":"crossref","first-page":"e000883","DOI":"10.1136\/jitc-2020-000883","article-title":"An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors","volume":"8","author":"Taylor","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2021.09.015_bib61","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/0008-5472.CAN-17-1318","article-title":"miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma","volume":"78","author":"D\u00edaz-Mart\u00ednez","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2021.09.015_bib62","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.stem.2018.05.016","article-title":"Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges","volume":"22","author":"Sneddon","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2021.09.015_bib63","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ebiom.2016.01.022","article-title":"CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy","volume":"5","author":"Pourchet","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2021.09.015_bib64","doi-asserted-by":"crossref","first-page":"89391","DOI":"10.18632\/oncotarget.20810","article-title":"Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma","volume":"8","author":"Panek","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2021.09.015_bib65","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.canlet.2016.07.019","article-title":"Mesenchymal stem cells deliver and release conditionally replicative adenovirus depending on hepatic differentiation to eliminate hepatocellular carcinoma cells specifically","volume":"381","author":"Yuan","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2021.09.015_bib66","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1038\/s41467-019-12794-2","article-title":"Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy","volume":"10","author":"Huang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.09.015_bib67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/1078-0432.CCR-1075-3","article-title":"Telomerase-specific replication-selective virotherapy for human cancer","volume":"10","author":"Kawashima","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2021.09.015_bib68","doi-asserted-by":"crossref","first-page":"105090","DOI":"10.1016\/j.ejps.2019.105090","article-title":"A novel method to purify adenovirus based on increasing salt concentrations in buffer","volume":"141","author":"Ma","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ymthe.2021.09.015_bib69","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.omtm.2020.08.013","article-title":"The Effect of Residual Triton X-100 on Structural Stability and Infection Activity of Adenovirus Particles","volume":"19","author":"Ma","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2021.09.015_bib70","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.biomaterials.2018.05.051","article-title":"Oxygen-boosted immunogenic photodynamic therapy with gold nanocages@manganese dioxide to inhibit tumor growth and metastases","volume":"177","author":"Liang","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2021.09.015_bib71","doi-asserted-by":"crossref","first-page":"e001180","DOI":"10.1136\/jitc-2020-001180","article-title":"Regulation of tumor growth by leukocyte-specific protein 1 in T\u00a0cells","volume":"8","author":"Kwon","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621004706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621004706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:49:40Z","timestamp":1777618180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001621004706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1525001621004706"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.09.015","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose VitC plus oncolytic adenoviruses enhance immunogenic tumor cell death and reprogram tumor immune microenvironment","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}